Richard Klausner Acquires 158,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner purchased 158,000 shares of the company’s stock in a transaction on Friday, March 14th. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $94,800.00. Following the completion of the transaction, the director now owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Lyell Immunopharma Trading Down 8.3 %

LYEL opened at $0.53 on Friday. The stock has a market cap of $157.45 million, a PE ratio of -0.68 and a beta of -0.41. Lyell Immunopharma, Inc. has a 1 year low of $0.48 and a 1 year high of $3.15. The stock’s 50 day simple moving average is $0.61 and its 200-day simple moving average is $0.89.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

A number of large investors have recently bought and sold shares of LYEL. Decheng Capital LLC bought a new stake in Lyell Immunopharma in the fourth quarter valued at $7,622,000. Foresite Capital Management V LLC bought a new stake in Lyell Immunopharma in the fourth quarter valued at $5,205,000. venBio Partners LLC bought a new stake in Lyell Immunopharma in the fourth quarter valued at $4,545,000. Renaissance Technologies LLC grew its position in Lyell Immunopharma by 716.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock valued at $1,032,000 after acquiring an additional 1,414,746 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Lyell Immunopharma in the fourth quarter valued at $887,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.